Kyle Nicholson

Find me on:

Recent Posts

Medication-Induced Syndromes Offer Growth Opportunity

Posted by Kyle Nicholson on Aug 15, 2016 1:40:17 PM

Opioid-induced constipation, tardive dyskinesia, and other medication-induced syndromes present worthwhile revenue opportunities for pharmaceutical R&D.

In the 1960s, researchers discovered that the loss of motor control from Parkinson’s disease (PD) was tied to a deficiency of dopamine in a part of the brain involved in the coordination of movement.

Evidence soon established that administration of levodopa, a dopamine precursor molecule, dramatically improved PD symptoms. Here’s the catch: relief of symptoms was accompanied by severe nausea and vomiting. Levodopa was not only being converted to dopamine in the brain but also in the bloodstream, activating dopamine receptors in the peripheral nervous system and causing the adverse side effects.

Read More

Topics: Pharma, Life Sciences, Product Positioning, Competitive Strategy

Fuld + Company Blog

The material on this page draws on the research and experience of Fuld + Company thought leaders, consultants and others. Learn more about our expertise here.

Recent Posts

Request for Information

If you'd like someone at Fuld to contact you regarding your strategic competitive challenges, fill out the form below.